Lidocaine IV for after thoracoscopic surgery :- Medznat
EN | RU
EN | RU

Help Support

Back

Lidocaine infusion eases post-thoracoscopic surgery pain

Postoperative pain management Postoperative pain management
Postoperative pain management Postoperative pain management

To examine the effectiveness of Lidocaine intravenous (IV) administration concerning post-operative morphine intake and pain levels following a video-assisted thoracoscopic surgery (VATS) when used peri-operatively.

See All

Key take away

Post-thoracic surgery, pain management persists as a challenge, with Lidocaine infusion displaying promise within multimodal analgesia, particularly for patients with contraindications to other analgesics.

Background

To examine the effectiveness of Lidocaine intravenous (IV) administration concerning post-operative morphine intake and pain levels following a video-assisted thoracoscopic surgery (VATS) when used peri-operatively.

Method

This trial employed a double-blind, placebo-controlled design in which the participants scheduled for VATS lasting up to 90 minutes were randomly assigned in an intention-to-treat fashion. 

They were administered either Lidocaine IV or a placebo, delivered as a bolus of 1.5 mg/kg 30 minutes before the surgical incision, followed by a continuous infusion of 3.0 mg/kg in an hour until 2 hours after the wound closure.

Pain levels and morphine usage were assessed during resting periods and episodes of coughing at intervals of 1 hour, 2 hours, 4 hours, 8 hours, 16 hours, 24 hours and 48 hours after closure. Additional assessments were made at 14, 90, and 180 days post-operation.

Result

The study encompassed 28 individuals in the Lidocaine group and 24 in the placebo group with comparable patient characteristics and pre-surgery pain scores. Notably, within 24 hours after wound closure, patients who received Lidocaine experienced significant pain relief when coughing than those in the placebo group (4.60±1.64 versus 5.52±1.65; P=0.02). 

However, the difference in morphine consumption between the Lidocaine and placebo groups was not statistically significant (18.22±12.87 vs. 21.26±9.39 mg; P=0.26). Secondary outcomes did not reveal any significant variances between the two groups.

Conclusion

Perioperative Lidocaine IV reduces pain scores after VATS. The positive clinical impacts are constrained.Top of Form

Source:

Journal of Thoracic Disease

Article:

Perioperative intravenous Lidocaine in thoracoscopic surgery for improved postoperative pain control: a randomized, placebo-controlled, double-blind, superiority trial

Authors:

Aljaz Hojski et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: